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Abstract 
 
Objectives: First, to report the distribution of fetal fraction and the rate of failed result in trisomies 
21, 18 and 13, by comparison with pregnancies unaffected by these trisomies, secondly, 
examine the possible effects of maternal and fetal characteristics on the fetal fraction and thirdly, 
consider the options for the further management of pregnancies with failed cfDNA result. 
 
Methods: This was a cohort study of 10,698 singleton pregnancies undergoing screening for 
fetal trisomies 21, 18 and 13 by cfDNA testing at 10-14 weeks’ gestation. There were 160 cases 
of trisomy 21, 50 of trisomy 18, 16 of trisomy 13 and 10,472 unaffected by these trisomies. 
Multivariate regression analysis was used to determine significant predictors of fetal fraction and 
failed result amongst maternal and fetal characteristics. 
 
Results: Fetal fraction decreased with increasing body mass index and maternal age, was lower 
in women of South Asian racial origin than in Caucasians and in assisted than natural 
conceptions, and increased with fetal crown-rump length, serum PAPP-A and free -hCG. The 
median fetal fraction was 11.0% (IQR 8.3-14.4%) in the unaffected group, 10.7% (IQR 7.8-
14.3%) in trisomy 21, 8.6% (IQR 5.0-10.2%) in trisomy 18 and 7.0% (IQR 6.0-9.4%) in trisomy 
13. There was a failed result from cfDNA testing after first sampling in 2.9% of the unaffected 
group, 1.9% of trisomy 21, 8.0% of trisomy 18 and 6.3% of trisomy 13. In the cases of failed 
result, 7% of women had invasive testing, mainly because of high-risk from the combined test 
and/or presence of sonographic features suggestive of trisomies 18 and 13. All cases of 
trisomies were detected prenatally.  
 
Conclusions: In cases of failed cfDNA test the rate of trisomies 18 and 13, but not trisomy 21, 
are higher than in those with a successful test. In the management of such cases, the decision 
in favor of invasive testing should depend on the risk of prior screening and the results of 
detailed ultrasound examination. 
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INTRODUCTION 
 
Cell-free (cf) DNA analysis of maternal blood provides effective screening for fetal trisomies 21, 
18 and 13 with reported detection rates (DR) of 99%, 96% and 91%, respectively, at overall 
false positive rate (FPR) of 0.35%.1 However, the test fails to provide a result in up to 8% of 
cases and the most common reason for such failure is low fetal fraction.2 There is some limited 
data that in the pregnancies with failed results fetal chromosomal abnormalities are over-
represented 2 and this has led to a recommendation by the American College of Obstetricians 
and Gynecologists (ACOG) that in cases of failed result women should be offered diagnostic 
testing 3. 
 
The objectives of this cohort study of 10,698 singleton pregnancies undergoing screening for 
fetal trisomies 21, 18 and 13 by cfDNA testing at 10-14 weeks’ gestation are to firstly, report the 
distribution of fetal fraction and the rate of failed result in each of the trisomies, by comparison 
with pregnancies unaffected by these trisomies, secondly, examine the possible effects of 
maternal and fetal characteristics on the fetal fraction and thirdly, consider the options for the 
further management of pregnancies with failed cfDNA result. 
 
 
METHODS 
 
The data for this study were derived from first, cfDNA testing as an option following first-
trimester combined testing in women with singleton pregnancies attending for routine care at 
11+0-13+6 weeks’ gestation in one of two National Health Service (NHS) hospitals in England 4  
and second, cfDNA testing as part of routine screening in women with singleton pregnancies at 
10+0-13+6 weeks attending the Fetal Medicine Centre in London, which is a private clinic 5. The 
patients were examined between October 2012 and August 2015. 
 
We recorded maternal characteristics and medical history, including maternal age, racial origin 
(Caucasian, African, South Asian, East Asian and mixed), method of conception (natural or 
assisted conception requiring the use of ovulation drugs or in-vitro fertilization), cigarette 
smoking during pregnancy (yes or no) and parity (parous or nulliparous if no previous 
pregnancy at or after 24 weeks’ gestation). We also measured maternal weight and height. In all 
cases free ß-hCG and PAPP-A were measured within 10 minutes of blood collection at 10+0-
13+6 weeks (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA, 
or Kryptor, Thermo Scientific, Berlin, Germany). An ultrasound scan was carried out at 11+0-13+6 
weeks to determine gestational age from the measurement of the fetal crown-rump length (CRL) 
6, diagnose any major fetal abnormalities and measure fetal nuchal translucency (NT) thickness. 
The measured NT was expressed as a difference from the expected normal mean for gestation 
(delta value) 7. Similarly, the measured free ß-hCG and PAPP-A were converted into multiple of 
the median (MoM) for gestational age adjusted for maternal weight, racial origin, smoking 
status, method of conception, parity and machine for the assays 8. Biophysical and biochemical 
markers were combined to estimate the patient-specific risk for trisomies 21, 18 and 13. 
 
Women provided written informed consent and maternal blood (20 mL) was sent via courier to 
the USA for cfDNA testing (HarmonyTM Prenatal Test, Ariosa Diagnostics, Inc., San Jose, CA) 9-
13. Chromosome-selective sequencing, referred to as digital analysis of selected regions (DANSR), 
and fetal-fraction optimized risk of trisomy evaluation (FORTE) were used to assay non-polymorphic 
and polymorphic loci, where fetal alleles differ from maternal alleles, enabling simultaneous 
determination of chromosome proportion and fetal fraction. The results from cfDNA testing were 
presented as risk scores for trisomy 21, 18, and 13 which in most cases were either >99% or 
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<1:10,000. In cases where the cfDNA test did not provide results the parents were offered 
repeat testing or to rely on the results of the combined test in deciding whether to have an 
invasive test or not. In cases with a high-risk result from the cfDNA test, the parents were 
advised to consider having invasive fetal karyotyping before deciding on the further 
management of their pregnancy.  
 
Patient characteristics and results of the investigations were recorded in a fetal database. 
Results from invasive testing, obtained from laboratories, and pregnancy outcome, obtained 
from obstetricians, general practitioners or the patients, were recorded in the same database. 
The outcomes were divided into firstly, trisomy 21, 18 or 13 if the karyotype of chorionic villi, 
amniotic fluid or neonatal blood demonstrated the relevant trisomy, secondly, no trisomy 21, 18 
or 13 if the karyotype of chorionic villi, amniotic fluid or neonatal blood was normal or the 
neonate was phenotypically normal, thirdly, no known karyotype because the pregnancies 
resulted in miscarriage or stillbirth and no karyotyping of fetal tissue was carried out, and 
fourthly, outcome unknown because the pregnancies were lost to follow up. 
 
Statistical analyses 
 
Descriptive data were presented in median and interquartile range (IQR) for continuous 
variables and in numbers and percentages for categorical variables. The measured fetal fraction 
was log10 transformed to make the distribution Gaussian, which was assessed using histograms 
and probability plots. Univariate and multivariate regression analysis were used to determine 
which of the factors amongst maternal age, body mass index, racial origin, smoking status, 
method of conception, fetal CRL, serum PAPP-A and free ß-hCG, fetal NT and fetal karyotype 
were significant predictors of log10 fetal fraction. In each trisomic and unaffected pregnancy the 
log10 fetal fraction was expressed as a MoM after adjusting for the maternal variables found to 
be significant in the multivariate regression analysis. Logistic regression analysis was 
undertaken to examine the maternal and pregnancy characteristics providing significant 
contribution to prediction of failed cfDNA test result. 
 
The statistical software package SPSS 21.0 (SPSS Inc.,Chicago, IL) was used for data 
analyses. 
 
Role of the funding source 
 
The study was supported by a grant from The Fetal Medicine Foundation (UK Charity No: 
1037116). The cost of collection and analysis of the samples for the cell-free DNA test in the 
NHS hospitals was covered by Ariosa Diagnostics, Inc. San Jose, CA, USA. These 
organizations had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. 
 
 
RESULTS 
 
Characteristics of study population 
 
A total of 10,963 women had cfDNA testing and combined screening for trisomies, but 265 
(2.4%) of these were excluded from further analysis either because the pregnancies ended in 
termination, miscarriage or stillbirth with no known karyotype (n=155), they were lost to follow 
up (n=85) or they had chromosomal abnormalities other than trisomies 21, 18 or 13 (n=25). 
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Maternal and pregnancy characteristics in the 10,698 cases with known outcome are 
summarized in Table 1. There were 160 cases of trisomy 21, 50 of trisomy 18, 16 of trisomy 13 
and 10,472 unaffected by these trisomies. Results from cfDNA testing were provided after first 
sampling for 97.0% (10,382/10,698) cases, including 97.1% in the unaffected group, 98.1% in 
trisomy 21, 92.0% in trisomy 18 and 93.7% in trisomy 13. The reasons for failure to provide a 
result were low fetal fraction in 219 (69.3%) cases and laboratory processing problems in 97 
(30.7%) cases.  
 
Factors affecting fetal fraction  
 
At first sampling, the median fetal fraction was 11.0% (IQR 8.3-14.4%) in the unaffected group, 
10.7% (IQR 7.8-14.3%) in trisomy 21, 8.6% (IQR 5.0-10.2%) in trisomy 18 and 7.0% (IQR 6.0-
9.4%) in trisomy 13; in these calculations, it was assumed that in the cases of failed result 
because of low fetal fraction, the fetal fraction was 3%. 
 
Log10 fetal fraction from first sampling had a Gaussian distribution (Figure 1). Univariate 
regression analysis demonstrated that significant independent prediction of log10 fetal fraction 
was provided by maternal age, body mass index, African, South Asian and East Asian  racial 
origin, assisted conception, fetal CRL, PAPP-A and free β-hCG MoM and trisomies 18 and 13 
(Table 2). In the multivariate regression analysis significant contribution was provided by 
maternal age, body mass index, South Asian racial origin, assisted conception, fetal CRL and 
PAPP-A and free β-hCG MoM, but not trisomies 18 or 13 (Adjusted R2=0.251, p<0.0001). If in 
the multivariate regression analysis we excluded PAPP-A and free β-hCG MoM, significant 
contribution to log10 fetal fraction was provided by maternal age, body mass index, South Asian 
racial origin, assisted conception, fetal CRL and trisomies 18 and 13 (Adjusted R2=0.174, 
p<0.0001). 
 
We used the coefficients of the maternal characteristics with significant contribution to log10 fetal 
fraction in the multivariate regression analysis to derive a model for calculation of MoMs. The 
median fetal fraction MoM in unaffected pregnancies was 1.03 (IQR 0.79-1.32). Compared to 
unaffected pregnancies, the fetal fraction MoM was not significantly different in trisomy 21 (0.99, 
IQR 0.77-1.29, p=0.527), but it was lower in those with trisomy 18 (0.80, IQR 0.49-1.05, 
p<0.0001) or trisomy 13 (0.71, IQR 0.54-0.90, p<0.0001) (Figure 2). If in the estimation of fetal 
fraction MoM we included the coefficients for PAPP-A and free β-hCG MoM, there were no 
significant differences between the unaffected pregnancies (1.03, IQR 0.81-1.30) and those with 
trisomy 21 (1.05, IQR 0.76-1.29; p=0.894), trisomy 18 (1.10, IQR 077-1.52; p=0.198) or trisomy 
13 (0.81, IQR 0.66-1.14; p=0.051).   
 
Multivariate logistic regression analysis demonstrated that the risk of test failure increased with 
increasing maternal age and body mass index, decreased with increasing PAPP-A and free β-
hCG MoM and it was higher in women of South Asian than Caucasian racial origin and in 
pregnancies achieved by assisted conception than naturally (Adjusted R2=0.212, p<0.0001).  
 
Management of pregnancies with cfDNA test failure 
 
There was a failed cfDNA result after first sampling in 2.9% (308/10,472) cases in the 
unaffected group, 1.9% (3/160) in trisomy 21, 8.0% (4/50) in trisomy 18 and 6.3% (1/16) in 
trisomy 13 (Table 3).  
 
In the 308 unaffected cases with failed cfDNA result, 234 (76.0%) chose repeat cfDNA testing, 8 
(2.6%) had invasive testing and 66 (21.4%) opted for no further investigations. Repeat cfDNA 
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testing provided a result in 147 (62.8%) of the 234 cases; 7 (8.0%) of the 87 with a failed 
second cfDNA test had invasive testing and 80 (92.0%) opted for no further investigations. In 
total, 15 (4.9%) of the 308 with failed cfDNA result ended up having an invasive test and in 13 
(86.7%) of the 15 cases in this group the estimated risk for trisomies from the combined test 
was >1 in 100. In contrast, 213 of the 308 cases did not have a result from the cfDNA test, 
either after first or repeat testing; in this group no invasive test was carried out and only 28 
(13.1%) had an estimated risk for trisomies from the combined test of >1 in 100. In contrast, in 
the 146 cases with no result from first or repeat cfDNA testing where the women decided 
against invasive testing, only 28 (13.1%) had an estimated risk for trisomies from the combined 
test of >1 in 100. 
 
In two of the three cases of trisomy 21 with failed cfDNA result, invasive testing was carried out 
because the estimated risk from the combined test was >1 in 3; in the third case with estimated 
risk of 1 in 13, the cfDNA test was repeated and this gave a result. In the four cases of trisomy 
18, invasive testing was carried out because in all cases the estimated risk from the combined 
test was >1 in 5, serum PAPP-A and free ß-hCG was <0.3 MoM and there were sonographic 
features suggestive of this trisomy, including clenched hands, cardiac defect and / or 
exomphalos. In the case of trisomy 13, invasive testing was carried out because the estimated 
risk from the combined test was 1 in 2, the fetal NT was 4.1 mm and the fetal heart rate was 200 
bpm. 
 
 
DISCUSSION 
 
Principal findings of this study 
 
In this study selective sequencing was used for cfDNA analysis of maternal blood in screening 
for fetal trisomies 21, 18 and 13 at 10-14 weeks’ gestation. The median fetal fraction was 11.0% 
and this decreased with increasing maternal age and body mass index, increased with fetal CRL 
and maternal serum free -hCG and PAPP-A and it was lower in women of South Asian racial 
origin than in Caucasians and in pregnancies conceived by assisted reproduction techniques 
than in natural conceptions. 
 
The median fetal fraction in pregnancies with fetal trisomy 21 was not significantly different from 
unaffected pregnancies. In trisomies 18 and 13 the fetal fraction was significantly reduced and 
this decrease could be explained by the association of these trisomies with low serum PAPP-A 
and free ß-hCG, reflecting the smaller placental source of fetal cfDNA in maternal blood. 
 
In 3% of pregnancies the cfDNA test failed to provide a result after first sampling and the main 
reason for such failure was low fetal fraction <4%. The rate of failed result was similar in 
unaffected and trisomy 21 cases, but this was increased in trisomy 18 and 13 pregnancies. 
Logistic regression analysis demonstrated that the risk of failed cfDNA test was inevitably 
affected by the same factors as those affecting fetal fraction. Thus, the rate of failed result 
increased with increasing maternal age and body mass index, decreased with increasing 
maternal serum level of free -hCG and PAPP-A and it was higher in women of South Asian 
racial origin than in Caucasians and in pregnancies conceived by assisted reproduction 
techniques than in natural conceptions. 
 
The options for the management of pregnancies with failed cfDNA test after first sampling 
include repeat cfDNA testing, invasive testing and no further investigations; similarly, the options 
for women with a second failed cfDNA test are invasive testing or no further investigations. An 
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important determinant for selecting the appropriate management option is the estimated risk for 
trisomies from the combined test and the presence of sonographic features suggestive of 
trisomies 18 and 13. In this study only 7% (22/316) with failed cfDNA test chose to have 
invasive testing and in 91% of these cases the estimated risk for trisomies from the combined 
test was >1 in 100. In contrast, in the patients with failed cfDNA test, either after first or repeat 
testing, that decided against invasive testing only 13% had an estimated risk for trisomies from 
the combined test of >1 in 100. 
 
Comparison of findings to those in previous studies 
 
The inverse association between fetal fraction and maternal body mass index, which could be 
attributed to a dilutional effect, but also increase in maternal cfDNA with increasing weight, is 
compatible with the results of previous cfDNA studies [12-15]. Similarly our finding of a linear 
association between fetal fraction and serum free -hCG and PAPP-A provides further support 
to our suggestion that since all three are produced by the placenta, their maternal serum levels 
provide an indirect measure of placental mass [12-14]. A 3-dimensional ultrasound study 
reported that in trisomy 21 pregnancies, placental volume at 11–13 weeks’ gestation was not 
significantly different from euploid pregnancies, but in trisomies 18 and 13 placental volume was 
decreased [16].  
 
In previous studies we found that the fetal fraction is decreased in women of African racial 
origin, primarily because of an increase in maternal cfDNA level rather than decrease in fetal 
cfDNA in maternal blood [12-14]. In this larger study, we found in the univariate analysis that in 
women of African racial origin the fetal fraction was significantly lower than in Caucasians, but in 
the multrivariate analysis this significance was lost. In contrast, in women of South Asian racial 
origin the fetal fraction was significantly reduced both in the univariate and multivariate analysis 
and this decrease may be a consequence of an increase in maternal cfDNA level, rather than 
decrease in fetal cfDNA in maternal blood [14]. 
 
The finding that in pregnancies conceived by assisted reproduction techniques the fetal fraction 
is lower than in natural conceptions is compatible with a previous report in multiple pregnancies 
[17] and this may be the consequence of a degree of impaired placentation which can also 
explain the higher incidence of associated pregnancy complications, such as preeclampsia [18]. 
 
A few studies compared fetal fraction in pregnancies with fetal trisomies 21, 18 and 13 with that 
in euploid pregnancies. Rava et al., examined high-risk pregnancies undergoing invasive testing 
at 10-23 weeks’ gestation, including 160 euploid pregnancies and 90, 38 and 16 with trisomies 
21, 18 and 13, respectively [19]. The mean fetal fraction in trisomy 21 (13.5%) was significantly 
higher and in trisomies 18 (8.9%) and 13 (9.0%) was lower than in euploid pregnancies (12.6%). 
Dar et al., reported the results of screening at a median gestational age of 13 (range 9-41) 
weeks, in 17,885 pregnancies, including 140 with trisomy 21, 27 with trisomy 18 and 8 with 
trisomy 13 [20]. The median fetal fraction was 10.1% and this increased with gestational age 
and decreased with maternal weight; after adjustment for these variables the median MoM fetal 
fraction in trisomy 21 (1.05 MoM) was significantly higher and in trisomies 18 (0.92 MoM) and 
13 (0.76 MoM) was lower than in euploid pregnancies (1.0 MoM). Palomaki et al., reported the 
results of a case-control study at a median gestational age of 15 (range 8-22) weeks, in 2,157 
pregnancies, including 212 with trisomy 21, 62 with trisomy 18 and 12 with trisomy 13 [21]. The 
median fetal fraction in trisomy 21 (15.5%) was higher and in trisomy 18 (9.4%) was lower than 
in euploid pregnancies (13.3%); the value in trisomy 13 was 13.6%. 
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Kinnings et al., reported the results of screening at a median gestational age of 13 (range 10-
40) weeks, in 140,377 pregnancies, including 2,214 with trisomy 21, 835 with trisomy 18 and 
432 with trisomy 13 [22]. The median fetal fraction increased with gestational age, decreased 
with maternal weight and was affected by the fetal aneuploidy status; the median value was 
9.6% for euploid and trisomy 21 pregnancies, 8.2% for trisomy 18 and 8.7% for trisomy 13. The 
study also demonstrated that the fetal fraction in trisomic, compared to euploid pregnancies, 
changed with gestational age; the fetal fraction was initially lower for all three trisomies but then 
became higher than in euploid pregnancies after 16, 21 and 18 weeks for trisomies 21, 18 and 
13, respectively [22]. 
 
Implications for practice  
 
On the basis of results from this and previous studies it can be concluded that in trisomies 18 
and 13, but not in trisomy 21, the fetal fraction is lower and the rate of failed cfDNA test is higher 
than in unaffected pregnancies. Consequently, pregnancies with a failed test can be considered 
as being at increased risk for trisomies 18 and 13, but not for trisomy 21. However, the results of 
the study of Kinnings et al., suggest that this problem of over-representation of trisomies 18 and 
13 in the pregnancies with failed cfDNA test is confined to pregnancies in the first half of 
pregnancy [22]. 
 
The management of pregnancies with failed cfDNA test should essentially depend on the 
reason for carrying out such test in the first place, as well as the cost of the cfDNA test; 
however, most companies accept to repeat the test at no additional cost. If there was prior 
screening with a low-risk result, the preferred option would be to repeat the cfDNA test and 
explain to the parents that such testing would provide a result in >60% of cases. Some patients 
would prefer to avoid any further testing because of the associated anxiety; in these patients 
and in those with a failed second cfDNA test it would be advisable to carry out a detailed 
ultrasound scan for features of trisomies 18 and 13 and in the presence of such features 
invasive testing should be considered. If prior screening had provided a high-risk result but there 
are no ultrasound features of an aneuploidy, most patients would prefer repeat cfDNA testing 
but a few would select to have invasive testing. 
 
Conclusions 
 
In cases of failed cfDNA test fetal trisomies 18 and 13, but not trisomy 21, are over-represented. 
In the management of such cases, the decision in favor of invasive testing should depend on 
the risk from prior screening and the results of detailed ultrasound examination. 
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Table 1. Maternal characteristics of the study population. 
 
 
Maternal and pregnancy characteristic 
Study population 
(n=10,698) 
Maternal age in years, median (IQR) 36.3 (33.2-39.3) 
Maternal weight in kg, median (IQR) 64.0 (57.9-73.0) 
Maternal height in cm, median (IQR) 165 (161-170) 
Racial origin  
   Caucasian, n (%) 8,751 (81.8) 
   African, n (%) 698 (6.5) 
   South Asian, n (%) 663 (6.2) 
   East Asian, n (%) 386 (3.6) 
   Mixed, n (%) 200 (1.9) 
Parity  
   Nulliparous, n (%) 4,760 (44.5) 
Cigarette smoker, n (%) 263 (2.5) 
Conception  
   Natural, n (%) 9,515 (88.9) 
   Assisted, n (%) 1,183 (11.1) 
Crown-rump length in mm, median (IQR) 53.7 (38.5-65.7) 
 
 
CRL = crown-rump length, NT = nuchal translucency, MoM = multiple of median, PAPP-A = 
pregnancy associated plasma protein-A, -hCG = -human chorionic gonadotropin, IQR = 
interquartile range 
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Table 2. Univariate and multivariate regression analysis demonstrating factors from maternal 
and pregnancy characteristics providing significant contribution to prediction of log10 
transformed fetal fraction 
 
 
CI = confidence interval; CRL = crown-rump length; MoM = multiple of the median; NT = nuchal 
translucency 
 
Independent variable 
Univariate analysis Multivariate analysis 
Regression coefficient (95% CI) P value Regression coefficient (95% CI) P value 
Intercept   1.451 (1.419 to 1.483) <0.0001 
Age in years -0.003 (-0.004 to -0.002) <0.0001 -0.002 (-0.003 to -0.001) <0.0001 
Body mass index, kg/m2 -0.016 (-0.016 to -0.015) <0.0001 -0.016 (-0.017 to -0.015) <0.0001 
Race origin     
   Caucasian  0.000 (reference)    
   African -0.055 (-0.070 to -0.039) <0.0001   
   South Asian -0.021 (-0.036 to -0.005) 0.011 -0.019 (-0.032 to -0.005) 0.008 
   East Asian 0.029 (0.009 to 0.050) 0.005   
   Mixed 0.022 (-0.006 to 0.051) 0.123   
Smoking 0.013 (-0.011 to 0.038) 0.293   
Assisted conception -0.089 (-0.101 to -0.077) <0.0001 -0.086 (-0.097 to -0.075) <0.0001 
Fetal CRL in mm 1.1e-04 (1.1 e-04 to 3.2e-04) 0.412 0.001 (4.7e-04 to 0.001) <0.0001 
Log10 PAPP-A MoM 0.166 (0.152 to 0.180) <0.0001 0.133 (0.119 to 0.146) <0.0001 
Log10 free β-hCG MoM 0.171 (0.158 to 0.184) <0.0001 0.140 (0.128 to 0.152) <0.0001 
Delta NT -0.003 (-0.009 to 0.002) 0.251   
Trisomy 21 0.003 (-0.028 to 0.035) 0.837   
Trisomy 18 -0.142 (-0.198 to -0.085) <0.0001   
Trisomy 13 -0.161 (-0.260 to -0.063) <0.0001   
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Table 3. Results from cfDNA testing and further management of pregnancy according to 
trisomic status of the fetus. 
 
 Non-trisomy Trisomy 21 Trisomy 18 Trisomy 13 
Number of cases 10,472 160 50 16 
Median fetal fraction     
 Percentage, median (IQR) 11.0 10.7 8.6 7.0 
  MoM, median (IQR) 1.03 (0.79-1.32) 0.99 (0.77-1.29 0.80 (0.49-1.05) 0.71 (0.54-0.90 
Failed result 308 (2.9) 3 (1.9) 4 (8.0) 1 (6.3) 
  Low fetal fraction 214 2 2 1 
  Laboratory processing 94 1 2  
Response to failed result     
  Invasive testing 8/308 (2.6) 2/3 (66.7) 4/4 (100) 1/1 (100) 
  No further test 66/308 (21.4)     
  Repeat testing 234/308 (76.0) 1/3 (33.3)   
    Result 147/234 (62.8) 1/1 (100)    
    Failed result 87 (37.2)    
       Invasive testing 7/87 (8.0)    
       No further test 80/87 (92.0)    
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Figure legends 
 
Figure 1. Frequency distribution of log10 fetal fraction in maternal blood cfDNA.  
 
Figure 2. Box and whisker plot of fetal fraction and fetal fraction multiple of median (MoM) in 
fetal trisomies and unaffected pregnancies. The MoMs were calculated from coefficients in 
Table 2  
 
